SLXN Silexion Therapeutics Corp: institutional ownership and insider trading
6 funds reported holding $42.5K of Silexion Therapeutics Corp in their latest 13F filings; in Q2 2026 funds net bought $43.4K, with 6 new positions and 0 funds selling out; over the last 12 months insiders bought $0 and sold $31.0K on the open market.
SLXN revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$3.55M, EPS 5.17
- Quarter ended Mar 31, 2026: revenue n/a, net income −$2.73M, EPS 8.46
- Quarter ended Dec 31, 2025: revenue n/a, net income −$4.41M, EPS 5.15
- Quarter ended Sep 30, 2025: revenue n/a, net income −$3.26M, EPS 2.88
Largest institutional holders of SLXN
- HRT FINANCIAL LP — $38.0K
- UBS Group AG (UBS) — $3.60K
- MONTAG A & ASSOCIATES INC — $765
- Pflug Koory, LLC — $84
- SBI Securities Co., Ltd. — $4
- ROYAL BANK OF CANADA (RY, RBMCF, RYLBF, RYPBF) — $0
Recent SLXN insider trades
- Mar 26, 2026: Shirvan Mitchell sold 22,818 shares ($31.0K)
5%+ owners
- Moringa Sponsor, LP: 17.7% (Schedule 13D/A, filed Sep 28, 2026)
- Moringa Partners Ltd: 14.7% (Schedule 13D/A, filed Sep 23, 2025)
- Lincoln Alternative Strategies LLC: 6.2% (Schedule 13G, filed Sep 15, 2025)
Who owns the most SLXN stock?
The largest institutional holders of Silexion Therapeutics Corp in the latest 13F filings are HRT FINANCIAL LP ($38.0K), UBS Group AG (UBS) ($3.60K), MONTAG A & ASSOCIATES INC ($765).
Are insiders buying or selling SLXN?
Over the last 12 months insiders bought $0 and sold $31.0K of Silexion Therapeutics Corp stock on the open market (SEC Form 4).